GlassScriptPhysician profile
Yuan Ying
NPI 1447612080
$1,890.31
in general payments reported to CMS, 2019-2025
11 companies · $324 in 2025
The $324 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $121 · 2020: $560 · 2021: $385 · 2022: $64.87 · 2023: $280 · 2024: $155 · 2025: $324.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $617 · Education: $142.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $616.85 |
| Education | $142.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $441.27 | 2020-2023 | Kyprolis |
| Janssen Biotech, INC. | $270.51 | 2025 | Rybrevant, Carvykti |
| Incyte Corporation | $206.18 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $205.64 | 2021-2024 | Calquence |
| Seagen INC. | $184.94 | 2020 | |
| Astellas Pharma US INC | $165.99 | 2020-2021 | |
| Pfizer INC. | $135.80 | 2022-2024 | |
| Lilly USA, LLC | $106.00 | 2019 | |
| Abbvie INC. | $105.66 | 2023 | Venclexta |
| Genentech USA, INC. | $53.45 | 2025 | |
| Genentech, INC. | $14.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yuan Ying listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.